![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, August 16, 2020 2:30:55 PM
This is an anonymous message board and no one knows who knows what and who is who. I have revealed some of my background in prior posts...but I could be lying...Free for all to judge. The fact that this question was asked, suggests that I may possess some credible info/intel, so here goes:
I am long. I have personally confirmed the science with multiple C Suite big pharma executives and a former “C” level type executive with the CDC, who is also a scientist. This gentleman has been approached by international companies to craft corporate responses to the pandemic...Science confirmed for 3X.
NP has historically been successful in raising $, yet, instead of doing so this year, he and his wife SOLD MILLIONS of $$ in STOCK, before any approvals have been obtained. These insider sales are still reverberating throughout the market and are magnified with each CYDY fail...Horrible leadership and bad optics move confirmed by 3X.
The Pro Active Video on the FDA Safety check revealed the pathological nature of fearless leader. It was 100% BS. We were told CYDY asked for the safety check in the promising hopes of emergency approval for S2C cohort. NP says In the video that the FDA requested the safety review and ... good news, we continue with trial. That just is not how it was touted. Watch the video...Lie confirmed by 3X.
I finally went back in my memory, with consultation of legacy personnel at CYDY, as well as actual paper work, to vet in my mind, the Pro 140 acquisition. NP has been touting HIS acquisition of Pro 140 (off the scrap heap) as a pied piper lure to kool aid drinking shareholders (and I was right there with them). I had not really paid attention or thought about the company history until now, but decided to dig. I remembered Ken Van Ness, a former CEO of CYDY (and former business partner of mine) mentioning Pro 140. At that time, I introduced KVN to a former BP executives circa 2011/2012. With NPs touting I thought maybe I mis-remembered. After looking at the signed 2012 Pro 140 agreement in the recently filed 10 K , my memory of actual events was restored. NPs character was further revealed (for each person to judge). NP individually rescuing Pro 14 off the scrap heap....debunked by 3X.
The last item above, is what many shareholders rely on to support NP : “if it was not for NP rescuing Pro140, we would not be here”. No and yes. He didn’t find it (he did help) and his lack of experience and knowledge or just plain arrogance landed us in a land of lost credibility, risk of NASDQ fail and no approvals.
It is amazing that so many medical people support this incompetence. It is my understanding that docs and nurses are trained to follow facts and threads. Do a “differential diagnosis” ( yes a House reference) on CYDY and answer why this great drug is still months away from any type of approval.
So... with all of the above now crystallized in my mind...3X calls for a shareholder revolt!
Let the board of directors know that this is too important to leave to “at best” , an executive with NO track record bringing a drug to market. If it is thought Leronlimab is a “ MIRACULOUS DRUG”, how is it responsible BOD stewardship to keep a neophyte at the helm?
At worst we have an incompetent egomaniac at the helm. See above, relative to the board responsibilities,
And same action required.
Make CYDY Great Again!
EMAIL the BOARD members and remind them of their responsibilities to shareholders and ask for justification for the retention of someone with no experience in this space, and who continues to fail at his job with so much at stake.
3X
God Bless America!
Recent CYDY News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 08/15/2024 09:21:30 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 07/22/2024 01:00:58 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/09/2024 09:17:48 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/09/2024 09:16:28 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 07/09/2024 09:16:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/09/2024 12:46:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 09:15:10 PM
- Form SC TO-I - Tender offer statement by Issuer • Edgar (US Regulatory) • 06/03/2024 09:10:56 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:17:30 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:16:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:09:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2024 02:30:20 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:16:47 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:15:34 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/22/2024 10:16:11 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/22/2024 05:15:08 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 02:00:24 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 10:31:57 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/29/2024 10:22:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2024 01:40:14 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/19/2024 10:15:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/16/2024 10:16:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:04:57 AM
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM
Swifty Global Reports Strong Q2 Performance and Prepares for Major Exchange Uplisting • DRCR • Aug 15, 2024 9:04 AM
Mayback's Global Entertainment Signs Global Distribution Agreement with Children's Media Studio • AHRO • Aug 15, 2024 8:45 AM
POET Technologies Reports Second Quarter 2024 Financial Results • POET • Aug 15, 2024 8:04 AM